Related Experiment Video
Updated: Jun 20, 2026

A Modified Method for Heterotopic Mouse Heart Transplantion
Published on: June 23, 2014
[Heart transplantation]
P Hude1, L Spinarová, J Krejcí
1I. interní kardio-angiologická klinika Lékarské fakulty MU a FN u sv. Anny Brno. petr.hude@fnusa.cz
Insights
Heart transplantation is a complex treatment for end-stage heart failure, requiring careful timing and lifelong immunosuppression. Future care depends on new drugs and non-invasive rejection diagnosis.
Area of Science:
- Cardiology
- Transplantation Medicine
- Immunology
Background:
- The first human heart transplantation occurred in 1967, with widespread clinical application emerging in the 1980s.
- Heart transplantation is a critical treatment for end-stage heart failure, but faces challenges due to limited donor organs and potential complications.
- Post-transplantation management involves lifelong immunosuppressive therapy and careful monitoring for drug interactions.
Purpose of the Study:
- To review the evolution and current status of heart transplantation.
- To highlight the complexities in patient selection and timing of heart transplantation.
- To discuss the challenges and future directions in managing heart transplant recipients.
Main Methods:
- Literature review of heart transplantation history, surgical advancements, and immunosuppressive strategies.
- Analysis of post-transplantation complications and management protocols.
- Discussion of current therapeutic approaches and future research needs.
Main Results:
- Heart transplantation has evolved from an experimental procedure to an established therapy for end-stage heart failure.
- Optimal timing and patient selection remain crucial for successful outcomes.
- Immunosuppression management is complex, requiring vigilance for drug interactions and adverse effects.
Conclusions:
- Despite advancements, heart transplantation involves significant challenges, including organ availability and post-operative complications.
- Long-term success hinges on meticulous pharmacological management and collaborative care between transplant teams and cardiologists.
- Future advancements require novel immunosuppressive agents with fewer side effects and non-invasive methods for diagnosing graft rejection.
Abstract:
The first heart transplantation (SHT) was performed by Professor Ch. Barnard in 1967 but it was not until 1980s that this method became an established approach to treatment of patients with end-stage heart failure. Considering the limited number of donor organs and the number of potential post-transplantation complications, the decision to perform heart transplantation at the right time in an indicated patient is difficult and complex. Subsequent pharmacological management with immunosuppressive agents and other medication becomes everyday life reality. Knowledge of drug interactions and collaboration with cardiologists are necessary in order to maintain long-term treatment success. Despite the current developments in surgical methods, examination methods and immunosuppressant therapy, a range of complications has to be dealt with. The future of care for patients with transplants will rely on the development of new immunosuppressive drugs with a minimum of adverse effects and discovery of a non-invasive technique for graft rejection diagnosis.
Related Concept Videos
Kidney Transplant I: Introduction
Cardiomyopathy V: Interprofessional Care
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Heart Failure VI: Adjunct Therapies

